Cabaletta Bio (NASDAQ:CABA) Receives Outperform Rating from William Blair

William Blair reissued their outperform rating on shares of Cabaletta Bio (NASDAQ:CABA) in a report issued on Monday,RTT News reports.

Several other equities analysts have also weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $25.00 target price on shares of Cabaletta Bio in a research note on Friday. UBS Group started coverage on Cabaletta Bio in a research note on Thursday, October 10th. They issued a “buy” rating and a $10.00 target price on the stock. Wells Fargo & Company cut their target price on Cabaletta Bio from $20.00 to $12.00 and set an “overweight” rating on the stock in a research note on Friday. Finally, Evercore ISI cut their target price on Cabaletta Bio from $25.00 to $15.00 and set an “outperform” rating on the stock in a research note on Monday, August 12th. Ten investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $27.30.

Cabaletta Bio Trading Down 10.9 %

NASDAQ:CABA opened at $2.70 on Monday. Cabaletta Bio has a 1-year low of $2.61 and a 1-year high of $26.35. The business’s 50-day moving average price is $4.20 and its two-hundred day moving average price is $6.79. The firm has a market capitalization of $131.89 million, a price-to-earnings ratio of -1.26 and a beta of 2.42.

Institutional Investors Weigh In On Cabaletta Bio

A number of hedge funds have recently modified their holdings of CABA. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Cabaletta Bio during the third quarter worth about $32,000. Point72 DIFC Ltd acquired a new stake in Cabaletta Bio in the 3rd quarter valued at approximately $33,000. China Universal Asset Management Co. Ltd. raised its position in Cabaletta Bio by 65.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,395 shares of the company’s stock valued at $44,000 after buying an additional 3,724 shares during the last quarter. Intech Investment Management LLC acquired a new stake in Cabaletta Bio in the 3rd quarter valued at approximately $67,000. Finally, GSA Capital Partners LLP acquired a new stake in Cabaletta Bio in the 3rd quarter valued at approximately $127,000.

Cabaletta Bio Company Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.